Tapentadol ER Shown to Be Effective for Chronic Diabetic Peripheral Neuropathy
A study presented at PAINWeek 2012 reported that tapentadol extended-release (ER) was effective and well tolerated for managing chronic diabetic peripheral neuropathy.
All articles by kevinzitzman
Hydrocodone Bitartrate ER Shown to be Effective for Chronic Pain
Hydrocodone Bitartrate ER may provide a new opioid option for subjects with chronic pain that is not alleviated by their current treatment, according to a study presented at PAINWeek 2012.
Once-Daily Gastroretentive Gabapentin Formulation Effective for Very Elderly with Postherpetic Neuralgia
A once-daily gastroretentive formulation of gabapentin, which for patients in the fed state lingers in the stomach for an estimated 8 hours, can be an efficacious option for postherpetic neuralgia, including a very elderly (age ≥75 years) population, as presented at PAINWeek 2012.
Hydromorphone ER Showed Similar Efficacy in Neuropathic and Non-Neuropathic Pain
Hydromorphone extended-release (ER) demonstrated similar efficacy in treating neuropathic or non-neuropathic chronic low back pain (LBP), as presented at PAINWeek 2012.
No Increased Cardiac Safety Risk with SC Methylnaltrexone for Chronic Pain
The cardiac safety of subcutaneous (SC) methylnaltrexone bromide is similar to placebo in patients with opioid-induced constipation and noncancer pain, reported Richard Rauck, MD, FIPP, of Carolinas Pain Institute, Winston-Salem, NC, at PAINWeek 2012.
Polyethylene Oxide Tapentadol ER Formulation Proves Crush-Resistant
At PAINWeek 2012, study data showed that tapentadol extended-release (ER) tablets formulated with a polyethylene oxide matrix produced tablets that were resistant to crushing or extraction, as reported by Joseph Pergolizzi, MD, of Naples Anesthesia and Pain Associates, Naples, FL.
Predictors Identify Patients Likely to Initiate New Medication for Diabetic Peripheral Neuropathy
At PAINWeek 2012, Wing Chow, PharmD, MPH, of Janssen Scientific Affairs, Raritan, NJ, and colleagues reported that the presence of prior antidepressant or anticonvulsant use is the most significant predictor of a patient receiving new medication for diabetic peripheral neuropathy (DPN).
Monitoring Common and Uncommon Adverse Events of Adjuvant and Co-Analgesics
At PAINWeek 2012, Christopher M. Herndon, PharmD, BCPS, CPE, presented different management and monitoring parameters of adverse events in non-opioid adjuvant and co-analgesics. Dr. Herndon specifically covered four major drug classes, discussing their common and uncommon adverse effects: non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen (APAP), antidepressants, and anticonvulsants.
Flurbiprofen Lozenge Provides Lasting Relief of Pharyngeal Pain
Flurbiprofen 8.75mg lozenge provides lasting relief of pharyngeal pain, noted Dr. Bernard Schachtel, from New York University, New York, NY, at the American Pain Society’s 31st Annual Scientific Meeting.
Liquid Capsaicin (NGX-1998) Provides PHN Relief After Five Minutes
At the American Pain Society’s 31st Annual Scientific Meeting, investigators reported that a 5-minute application of NGX-1998, a novel liquid formulation of high concentration capsaicin (10% and 20% w/w) provided effective pain relief for up to 12 weeks for the management of peripheral neuropathic pain associated with postherpetic neuralgia (PHN).
